[New treatments for systemic diseases].
Bader-Meunier
B
B
Service de pédiatrie générale, hôpital de Bicêtre, 94270 Le-Kremlin-Bicêtre, France. brigitte.bader-meunier@bct.aphp.fr
Willems
M
M
D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology*; D000974:Antibodies, Antinuclear / Q000097:blood; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D016026:Bone Marrow Transplantation; D002648:Child; D017277:Drug Approval; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000276:immunology; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069283:Rituximab; D000079424:Tumor Necrosis Factor Inhibitors; D014657:Vasculitis / Q000188:drug therapy* / Q000276:immunology
D019268:Antibodies, Antineutrophil Cytoplasmic; D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007166:Immunosuppressive Agents; D000079424:Tumor Necrosis Factor Inhibitors; D000069283:Rituximab; D007168:IMP Dehydrogenase; D009173:Mycophenolic Acid